Q1 2026 Biogen Inc Earnings Call Transcript
Key Points
- Biogen Inc (BIIB) reported a strong start to 2026 with total revenue of $2.5 billion, up 2% year-over-year.
- Growth products generated $851 million in revenue, marking a 12% increase year-over-year.
- The high dose SPINRAZA has been approved in the US, Japan, and Europe, with positive feedback and patient uptake.
- The proposed acquisition of Apellis is expected to be accretive in 2027, enhancing Biogen's commercial growth portfolio.
- Biogen's late-stage pipeline shows promise with multiple data readouts expected over the next 18 months, potentially strengthening growth outlook.
- SPINRAZA revenue declined slightly due to timing of shipments and a one-off VAT event in Europe.
- The market for geographic atrophy is highly competitive, with evolving dynamics and other agents focusing on visual acuity.
- Biogen's pipeline is thin in early-stage development, necessitating a focus on business development for future growth.
- The acquisition of Apellis involves significant financial commitments, including $2 billion in new borrowings.
- The nephrology market is becoming increasingly competitive, with multiple companies recruiting in the space.
Good morning. My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen first-quarter 2026 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you.
I would now like to turn the conference over to Mr. Tim Power, Head of Investor Relations. Mr. Power, you may begin your conference.
Well, thank you, and good morning, and welcome to Biogen's first-quarter 2026 earnings call. During this call, we will make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which we encourage you to review.
Our earnings release and other documents related to our results as well as reconciliations between GAAP and non-GAAP results discussed on this call can be found in the Investors section of biogen.com. We've also posted
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
